{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T13:15:44Z","timestamp":1785417344761,"version":"3.56.0"},"reference-count":41,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"Regensburg Faculty of Medicine","award":["Clinical Scientist Programme"],"award-info":[{"award-number":["Clinical Scientist Programme"]}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2026,3,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Vancomycin remains a key treatment for infections caused by \u03b2-lactam-resistant gram-positive cocci. While there is unanimity that only drug not bound to plasma proteins is pharmacologically active, a wide range of values and interdependencies for the unbound fraction (\n                      <jats:italic toggle=\"yes\">f<\/jats:italic>\n                      <jats:sub>u<\/jats:sub>\n                      ) of vancomycin have been reported in the past. In the present study, we evaluated 706 plasma samples from 228 adult in-patients who were sent for therapeutic drug monitoring. Total and free concentrations of vancomycin were analyzed by a validated method using ultrafiltration and HPLC-UV. Covariate effects on\n                      <jats:italic toggle=\"yes\">f<\/jats:italic>\n                      <jats:sub>u<\/jats:sub>\n                      were assessed by a linear mixed-effects model. The mean unbound fraction was 72.2 \u00b1 5.5% (coefficient of variation 7.7%, range 53\u201393%), the intra-individual and inter-individual variability were low (median coefficient of variation 5.7% and 6.4%, respectively). The unbound fraction was independent of total vancomycin, plasma albumin or total protein concentrations, or other biochemical or demographic variables, and did not differ between patients treated inside or outside of intensive care (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.465). Linear mixed-effects modeling confirmed low overall variability (coefficient of variation 7.0%), decomposed into 2.2% inter-individual, 3.8% inter-occasion, and 5.5% residual variability. Method comparison showed an excellent agreement between high-performance liquid chromatography with ultraviolet detection (HPLC-UV) and the immunoassay used for routine drug monitoring (bias +0.2%). Free concentrations of vancomycin can be reliably predicted from total concentrations. An unbound fraction of approximately 70% provides a robust and clinically useful estimate. Remaining variability appears to be primarily methodological, and not of clinical relevance.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1128\/aac.01593-25","type":"journal-article","created":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T13:00:36Z","timestamp":1769432436000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":0,"title":["Protein binding of vancomycin in a large mixed patient population at a university hospital"],"prefix":"10.1128","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1985-2102","authenticated-orcid":true,"given":"Alexander","family":"Dejaco","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01226dv09","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Anaesthesiology, University Hospital Regensburg","place":["Regensburg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4793-1443","authenticated-orcid":true,"given":"Constantin","family":"Lier","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01eezs655","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Pharmaceutical and Medicinal Chemistry I, University of Regensburg","place":["Regensburg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Krautbauer","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01226dv09","id-type":"ROR","asserted-by":"publisher"}],"name":"Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg","place":["Regensburg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2313-2968","authenticated-orcid":true,"given":"Frieder","family":"Kees","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01eezs655","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Pharmacology, University of Regensburg","place":["Regensburg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2560-9598","authenticated-orcid":true,"given":"Christoph","family":"Dorn","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01eezs655","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Pharmaceutical and Medicinal Chemistry I, University of Regensburg","place":["Regensburg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1708-0265","authenticated-orcid":false,"given":"Martin G.","family":"Kees","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01226dv09","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Anaesthesiology, University Hospital Regensburg","place":["Regensburg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.1086\/491708"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2018.08.034"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp080434"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxaa036"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000944"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaf041"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki079"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01185-15"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2009.08.005"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01674-10"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00951-13"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.4155\/bio.13.338"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2011.12.018"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.4155\/bio-2017-0053"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1080\/17576180.2024.2365526"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.175"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1177\/106002808802200404"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1984.260"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1980.tb01696.x"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/1056-8719(92)90066-a"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.11250\/chemotherapy1953.40.210"},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.32.6.848"},{"key":"e_1_3_6_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.2510120902"},{"key":"e_1_3_6_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.5.1132"},{"key":"e_1_3_6_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199001000-00006"},{"key":"e_1_3_6_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004630-198909000-00010"},{"key":"e_1_3_6_28_2","volume-title":"Goodman & Gilman\u2019s: the pharmacological basis of therapeutics","author":"Brunton LL","year":"2023","unstructured":"Brunton LL, Knollmann BC, eds. 2023. Goodman & Gilman\u2019s: the pharmacological basis of therapeutics. 14th ed. AccessPharmacy, McGraw Hill Medical, New York, USA.","edition":"14"},{"key":"e_1_3_6_29_2","unstructured":"Bowmed Ibisqus Limited. Vancomycin 500mg powder for concentrate for solution for infusion vials - Summary of Product Characteristics (SmPC). Retrieved 12 Aug 2025. https:\/\/www.medicines.org.uk\/emc\/product\/8759\/smpc\/print."},{"key":"e_1_3_6_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.34.7.1459"},{"key":"e_1_3_6_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2014.08.002"},{"key":"e_1_3_6_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.5559"},{"key":"e_1_3_6_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1323"},{"key":"e_1_3_6_34_2","doi-asserted-by":"publisher","DOI":"10.1177\/106002809102500701"},{"key":"e_1_3_6_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.1996.tb03028.x"},{"key":"e_1_3_6_36_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199504000-00001"},{"key":"e_1_3_6_37_2","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000122"},{"key":"e_1_3_6_38_2","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000001292"},{"key":"e_1_3_6_39_2","doi-asserted-by":"publisher","DOI":"10.4155\/bio.13.274"},{"key":"e_1_3_6_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2014.12.012"},{"key":"e_1_3_6_41_2","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000827"},{"key":"e_1_3_6_42_2","unstructured":"International Conference on Harmonization (ICH). 2023. Guideline on bioanalytical method validation and study sample analysis M10. Available from: https:\/\/www.ema.europa.eu\/en\/ich-m10-bioanalytical-method-validation-scientific-guideline. Retrieved 21 Jan 2025."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01593-25","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01593-25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T14:01:20Z","timestamp":1772632880000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.01593-25"}},"subtitle":[],"editor":[{"given":"James E.","family":"Leggett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,4]]}},"alternative-id":["10.1128\/aac.01593-25"],"URL":"https:\/\/doi.org\/10.1128\/aac.01593-25","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]},"assertion":[{"value":"2025-10-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01593-25"}}